
Richard A Koup

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3875431/publications.pdf Version: 2024-02-01



RICHARD & KOUR

#	Article	IF	CITATIONS
1	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
2	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	2.9	19
3	Human lymph node immune dynamics as driver of vaccine efficacy: an understudied aspect of immune responses. Expert Review of Vaccines, 2022, 21, 633-644.	2.0	2
4	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	3.2	13
5	Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. Journal of Experimental Medicine, 2021, 218, .	4.2	31
6	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCl Insight, 2021, 6, .	2.3	43
7	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathogens, 2021, 17, e1009339.	2.1	32
8	<i>Plasmodium falciparum</i> –specific IgM B cells dominate in children, expand with malaria, and produce functional IgM. Journal of Experimental Medicine, 2021, 218, .	4.2	44
9	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. Cell Reports, 2021, 35, 108937.	2.9	12
10	Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	11
11	In Situ Characterization of Human Lymphoid Tissue Immune Cells by Multispectral Confocal Imaging and Quantitative Image Analysis; Implications for HIV Reservoir Characterization. Frontiers in Immunology, 2021, 12, 683396.	2.2	11
12	Clonotypic architecture of a Gagâ€specific CD8+ Tâ€cell response in chronic human HIVâ€2 infection. European Journal of Immunology, 2021, 51, 2485-2500.	1.6	0
13	A government-led effort to identify correlates of protection for COVID-19 vaccines. Nature Medicine, 2021, 27, 1493-1494.	15.2	26
14	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	3.9	1
15	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	6.0	145
16	Compromised steadyâ€state germinal center activity with age in nonhuman primates. Aging Cell, 2020, 19, e13087.	3.0	23
17	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763.	3.3	53
18	lmmune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cell Reports, 2020, 32, 107981.	2.9	15

RICHARD A KOUP

#	Article	IF	CITATIONS
19	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
20	Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. Cell Host and Microbe, 2019, 26, 748-763.e20.	5.1	30
21	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. Journal of Virology, 2018, 92, .	1.5	30
22	New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. Annual Review of Medicine, 2018, 69, 409-419.	5.0	28
23	Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. Journal of Immunology, 2018, 200, 538-550.	0.4	38
24	Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance—Supercontrollers. Frontiers in Immunology, 2018, 9, 2897.	2.2	15
25	Elderly human hematopoietic progenitor cells express cellular senescence markers and are more susceptible to pyroptosis. JCI Insight, 2018, 3, .	2.3	38
26	Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals. Frontiers in Immunology, 2018, 9, 2500.	2.2	7
27	The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses. Retrovirology, 2018, 15, 54.	0.9	27
28	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493.	3.9	174
29	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. Journal of Clinical Investigation, 2018, 128, 2089-2103.	3.9	43
30	Lymphoid tissue fibrosis is associated with impaired vaccine responses. Journal of Clinical Investigation, 2018, 128, 2763-2773.	3.9	55
31	Altered immune cell follicular dynamics in HIV infection following influenza vaccination. Journal of Clinical Investigation, 2018, 128, 3171-3185.	3.9	34
32	Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine, 2017, 376, 928-938.	13.9	243
33	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	5.8	135
34	<scp>HIV</scp> antibodies for treatment of <scp>HIV</scp> infection. Immunological Reviews, 2017, 275, 313-323.	2.8	59
35	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1725-1733.	1.9	196
36	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	40

RICHARD A KOUP

#	Article	IF	CITATIONS
37	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	13.7	244
38	Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. MBio, 2017, 8, .	1.8	97
39	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	6.0	225
40	HIV-Specific CD8+ T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue. Cell Reports, 2017, 21, 3458-3470.	2.9	77
41	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	2.9	30
42	Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathogens, 2017, 13, e1006397.	2.1	58
43	Lower Baseline Germinal Center Activity and Preserved Th1 Immunity are Associated with Hepatitis B Vaccine Response in Treated HIV Infection. Pathogens and Immunity, 2017, 2, 66.	1.4	12
44	Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS ONE, 2016, 11, e0158262.	1.1	20
45	Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell, 2016, 166, 1004-1015.	13.5	156
46	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	13.9	391
47	Fineâ€ŧuning of CD8 ⁺ Tâ€cell effector functions by targeting the 2B4â€CD48 interaction. Immunology and Cell Biology, 2016, 94, 583-592.	1.0	6
48	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Journal of Virology, 2016, 90, 1321-1332.	1.5	68
49	The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. PLoS Pathogens, 2016, 12, e1006031.	2.1	35
50	Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE, 2015, 10, e0144767.	1.1	16
51	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	5.8	390
52	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, 298ra120.	5.8	119
53	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, 8447.	5.8	88
54	IFNγ ^{â^'} TNFα ^{â^'} IL2 ^{â^'} MIP1α ^{â^'} CD107a ⁺ PRF1< pp65-Specific T-Cell Response Is Independently Associated With Time to Death in Elderly Humans.	sup>+ <td>up>CD8 11</td>	up>CD8 11

pp65-Specific T-Cell Response Is Independently Associated With Time to Death in Elderly Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1210-1218. 54

RICHARD A KOUP

#	Article	IF	CITATIONS
55	HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. PLoS ONE, 2015, 10, e0140978.	1.1	49
56	T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. PLoS Pathogens, 2014, 10, e1004251.	2.1	273
57	Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection. PLoS Pathogens, 2014, 10, e1003853.	2.1	153
58	Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8 ⁺ T Cell Responses on HIV Set Point. Journal of Virology, 2014, 88, 1819-1824.	1.5	36
59	Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine, 2014, 32, 717-724.	1.7	21
60	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . Journal of Virology, 2014, 88, 12669-12682.	1.5	248
61	Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. Journal of Virology, 2014, 88, 4047-4057.	1.5	220
62	CD4 T follicular helper cell dynamics during SIV infection. Journal of Clinical Investigation, 2012, 122, 3281-3294.	3.9	307
63	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood, 2011, 117, 4805-4815.	0.6	193
64	Vaccine Design for CD8 T Lymphocyte Responses. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a007252-a007252.	2.9	105
65	Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials. Journal of Virology, 2009, 83, 6318-6322.	1.5	31
66	Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus–adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. Journal of General Virology, 2009, 90, 1600-1610.	1.3	55
67	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006, 107, 4781-4789.	0.6	1,681
68	Keratinocyte Growth Factor Increases Thymic Output of Nail̀^ve T-Cells after Total Body Irradiation and Autologous Peripheral Blood Progenitor Cell Transplantation in Rhesus Macaques Blood, 2005, 106, 187-187.	0.6	2